Investigating new treatments for advanced prostate cancer using novel drug compounds
Official title: Structure, function, and application of novel antagonists of the intrinsically disordered androgen receptor amino-terminal domain as imaging agents and therapeutics
Funded at Provincial Health Services Authority · NIH-10903756 · Data updated 2026-11-12
This study is looking for new treatments that can help fight prostate cancer by blocking a part of the androgen receptor that helps the cancer grow, and it also aims to create special imaging tools to better identify different types of cancer spread in patients, so doctors can make smarter treatment choices.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Provincial Health Services Authority NIH-funded |
| Lab location | 1 site (Vancouver, Canada) |
| Project start | July 13, 2021 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $423,596 |
| NIH project number | 5R01CA255044-04 |
| Project ID | NIH-10903756 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with advanced prostate cancer, particularly those with metastatic lesions expressing androgen receptor splice variants.
✕Less likely to help
Patients with early-stage prostate cancer or those not expressing androgen receptor splice variants may not benefit from this research.
What this research studies
This research focuses on developing new therapeutic agents that target the N-terminal domain of the androgen receptor, which is crucial for the growth of prostate cancer. The study aims to identify small molecules that can effectively block the activity of both full-length androgen receptors and their truncated variants, which are responsible for treatment resistance. By utilizing advanced techniques, the research seeks to create imaging agents that can help distinguish between different types of metastatic lesions in prostate cancer patients, ultimately guiding more effective treatment decisions.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for advanced prostate cancer, improving patient outcomes and survival rates.
How similar studies have gone: Previous research has shown promise in targeting androgen receptors in prostate cancer, but this approach focusing on the N-terminal domain is relatively novel.
Where this research is happening
-
Provincial Health Services Authority
Vancouver, Canada Active
Researchers
- Principal investigator: Sadar, Marianne D — Provincial Health Services Authority
- Study coordinator: Sadar, Marianne D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.